F182112 for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, F182112, for people whose multiple myeloma came back or didn't respond to prior treatments that included lenalidomide and a proteasome inhibitor. It may help if your disease has active signs like high protein levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has returned or not responded to treatment.
- Your past treatments must have included lenalidomide (taken for at least 2 cycles) and a proteasome inhibitor.
- You cannot have used pomalidomide in the past or been unable to tolerate it.
- You should be able to take care of yourself (ECOG score 0-2).
- Your disease must be measurable, like having high M-protein in blood or urine, or abnormal free light chains.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
This trial tests a new CAR-T cell therapy called GC012F for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this treatment can help control the disease.
This trial tests a new CAR-T cell therapy called LCAR-F33S for people with multiple myeloma that has returned or stopped responding to standard treatments. It aims to see if targeting a specific protein on myeloma cells can help control the disease.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.